Clinical trial
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
NCT00349557 · Benaroya Research Institute, Other · Completed
Key facts
| NCT number | NCT00349557 |
|---|---|
| Title | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer |
| Official title | Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer |
| Lead sponsor | Benaroya Research Institute, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT) |
| Enrollment | 18 |
| Start date | Apr 1, 2006 |
| First posted | Jul 7, 2006 |
| Last update posted | Jul 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: